Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.39 |
| ▸ | ATXN2 | Q99700 | 4/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LSS | P48449 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538482 | 0.93 | CHRM1 (0.41) | CHRM1HRH2HRH1KCNH2ENPP2 | |
| SCHEMBL5538475 | 0.93 | CHRM1 (0.41) | CHRM1HRH2HRH1KCNH2ENPP2 | |
| SCHEMBL5539665 | 0.89 | LSS (0.42) | HRH2HRH1KCNH2ALDH1A1LMNA | |
| SCHEMBL5539659 | 0.89 | LSS (0.42) | HRH2HRH1KCNH2ALDH1A1LMNA | |
| SCHEMBL5540287 | 0.88 | FNTA (0.40) | ALDH1A1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL58326 | 0.84 | PTGS1 (0.44) | CHRM1KCNH2ENPP2ALDH1A1LMNA | |
| SCHEMBL58327 | 0.84 | PTGS1 (0.44) | CHRM1KCNH2ENPP2ALDH1A1LMNA | |
| SCHEMBL5536163 | 0.83 | PTGS1 (0.43) | HRH2HRH1KCNH2ENPP2ALDH1A1 | |
| SCHEMBL5536156 | 0.83 | PTGS1 (0.43) | HRH2HRH1KCNH2ENPP2ALDH1A1 | |
| SCHEMBL5538319 | 0.83 | CHRM1 (0.41) | CHRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CHRM1 463/4885HRH2 730/4885HRH1 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.